1
/
of
1
Human Tumor Necrosis Factor Receptor Superfamily Member 6 (FAS) ELISA Kit
Human Tumor Necrosis Factor Receptor Superfamily Member 6 (FAS) ELISA Kit
This ELISA kit is designed to detect Human Tumor Necrosis Factor Receptor Superfamily Member 6 (Human FAS). The assay plate has been pre-coated with mouse anti-Human Fas monoclonal antibody. When the sample containing Fas is added to the plate, it binds to the antibodies coated on the wells. Then, a horseradish peroxidase conjugated mouse anti-Human Fas Antibody is added to the wells and binds to Fas in the sample. After washing the wells, substrate solutions are added, and the color intensity is directly proportional to the amount of Human Fas present. The reaction is stopped by adding an acidic stop solution, and the absorbance is measured at 450 nm.
Catalog No:
BPE047
Regular price
$624.00 USD
Regular price
$480.00 USD
Sale price
$624.00 USD
Unit price
/
per
2 weeks
Couldn't load pickup availability
Product Details
Species Reactivity
Human
Sensitivity
1.08 pg/mL
Detection Range
4.69-300 pg/mL
Sample Type
Serum, plasma, cell culture supernates
Incubation(s)
3.5 hour(s)
Research Areas
Cell Biology, Immunology
Background
CD95 (APO-1/Fas) is an important inducer of the extrinsic apoptosis signaling pathway and therapy induced apoptosis of many tumor cells has been linked to the activity of CD95. is a prototype death receptor characterized by the presence of an 80 amino acid death domain in its cytoplasmic tail. This domain is essential for the recruitment of a number of signaling components upon activation by either agonistic anti-CD95 antibodies or cognate CD95 ligand that initiate apoptosis. The complex of proteins that forms upon triggering of CD95 is called the death-inducting signaling complex (DISC). The DISC consists of an adaptor protein and initiator caspases and is essential for induction of apoptosis. CD95 is also crucial for the negative selection of B cells within the germinal center (GC). Impairment of CD95-mediated apoptosis results in defective affinity maturation and the persistence of autoreactive B-cell clones. Changes in the expression of CD95 and/or its ligand CD95L are frequently found in human cancer. The downregulation or mutation of CD95 has been proposed as a mechanism by which cancer cells avoid destruction by the immune system through reduced apoptosis sensitivity. Thus, CD95 has therefore been viewed as a tumor suppressor. CD95 has been reported to be involved in the activation of NF-kappaB, MAPK3/ERK1, MAPK8/JNK, and the alternate pathways for CTL-mediated cytotoxicity. Accordingly, this protein is implicated in the pathogenesis of various malignancies and diseases of the immune system. The CD95/CD95L system was implicated in the etiology of inflammatory bowel disease (IBD) based, primarily, on the finding that CD95 is highly expressed in the intestinal epithelial cells and that epithelial apoptosis is increased in IBD.
Shipping Condition
Shipped on cold gel packs.
Storage Condition and Shelf Life
This product can be stored at 2-8C.
Analyte
Tumor necrosis factor receptor superfamily member 6
Regulatory Status
For Research Use Only
